Supplementary Table S2 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Mark Yarchoan,John D. Powderly,Bruno R. Bastos,Thomas B. Karasic, Oxana V. Crysler,Pamela N. Munster,Meredith A. McKean,Leisha A. Emens, Yvonne M. Saenger,Yasser Ged,Robert Stagg, Steven Smith,Chan C. Whiting,Anne Moon,Peppi Prasit,Yonchu Jenkins,Nathan Standifer,Thomas W. Dubensky,Sam H. Whiting,Susanna V. Ulahannan

crossref（2024）

引用 0|浏览1

暂无评分

摘要

Summary of pharmacokinetics of 600 mg TPST-1120 twice daily as a single agent and in combination with nivolumab after single dose or at steady state (cycle 1 day 8)

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要